Regulatory Considerations for Raw Materials Used in Biological Products

References

1. 1.↵
   1. Anderson K. P.,
   2. Low M. A.,
   3. Lie Y. S.,
   4. Keller G. A.,
   5. Dinowitz M.

   Endogenous origin of defective retrovirus-like particles from a recombinant Chinese hamster ovary cell line. Virology 1991, 181 (1), 305–311.

   OpenUrlPubMed
2. 2.↵
   1. Khan A. S.,
   2. Maudru T.,
   3. Thompson A.,
   4. Muller J.,
   5. Sears J. F.,
   6. Peden K. W.

   The reverse transcriptase activity in cell-free medium of chicken embryo fibroblast cultures is not associated with a replication-competent retrovirus. J. Clin. Virol. 1998, 11 (1): 7–18.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Robertson J. S.,
   2. Nicolson C.,
   3. Riley A. M.,
   4. Bentley M.,
   5. Dunn G.,
   6. Corcoran T.,
   7. Schild G. C.,
   8. Minor P.

   Assessing the significance of reverse transcriptase activity in chick cell-derived vaccines. Biologicals 1997, 25 (4), 401–414.

   OpenUrl
4. 4.↵
   1. Tsang S. X.,
   2. Switzer W. M.,
   3. Shanmugam V.,
   4. Johnson J. A.,
   5. Goldsmith C.,
   6. Wright A.,
   7. Fadly A.,
   8. Thea D.,
   9. Jaffe H.,
   10. Folks T. M.,
   11. Heneine W.

   Evidence of avian leukosis virus subgroup E and endogenous avian virus in measles and mumps derived from chicken cells: investigation of transmission to vaccine recipients. J. Virol. 1999, 73 (7), 5843–5851.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Weissmahr R. N.,
   2. Schupbach J.,
   3. Boni J.

   Reverse transcriptase activity in chicken supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA. J. Virol. 1997, 71 (4), 3005–3012.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Waters T. D.,
   2. Anderson P. S. Jr..,
   3. Beebe G. W.,
   4. Miller R. W.

   Yellow fever vaccination, avian leukosis virus, and cancer risk in man. Science 1972, 177 (43), 76–77.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Melnick J. L.,
   2. Stinebaugh S.

   Excretion of vaculoating SV-40 virus (papova virus group) after ingestion as a contaminant of oral poliovaccine. Proc. Soc. Exp. Biol. Med. 1962, 109, 965–968.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Sweet B. H.,
   2. Hilleman M. R.

   The vacuolating virus SV 40. Proc. Soc. Exp. Biol. Med. 1960, 105, 420–427.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Li T.-C.,
   2. Scotti P. D.,
   3. Miyamura T.,
   4. Tadeka N.

   Latent infection of a new alphanodavirus in an insect cell line. J. Virol. 2007, 81 (20), 10890–10896.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Gurtler L.

    Blood-borne viral infections. Blood Coagul. Fibrinolysis 1994, 5 (Suppl. 3), S5–S12.

    OpenUrl
11. 11.↵
    1. Horowitz B.

    Specific Inactivation of Viruses Which Can Potentially Contaminate Blood Products. In Virological Aspects of the Safety of Biological Products; Karger: Basel, 1991; Vol. 75, pp 43–52.

    OpenUrl
12. 12.↵
    1. Horaud F.,
    2. Brown F.

    1. Vicari G.

    Validation of Purification Procedures for Removing and/or Inactivating Viruses in Biologicals: Points To Consider. In Virological Aspects of the Safety of Biological Products; Horaud F., Brown F., Eds.; Karger: Basel, 1991; Vol. 75, pp 227–232.

    OpenUrl
13. 13.↵
    1. Hollak C. E. M.,
    2. vom Dahi S.,
    3. Aerts J. M.,
    4. Belmatoug N.,
    5. Bembi B.,
    6. Cohen Y.,
    7. Collin-Histed T.,
    8. Deegan P.,
    9. van Dussen L.,
    10. Giraldo P.,
    11. Mengel E.,
    12. Michelakakis H.,
    13. Manuel J.,
    14. Hrebicek M.,
    15. Parini R.,
    16. Reinke J.,
    17. di Rocco M.,
    18. Pocovi M.,
    19. Sa Miranda MC.,
    20. Tylki-Szymanska A.,
    21. Zimran A.,
    22. Cox TM.

    Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol. Dis. 2010, 44 (1), 41–47.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    http://www.fda.gov/cber/advisoryvrbp/vrbpmain.htm.
15. 15.↵
    1. Victoria J. G.,
    2. Wang C.,
    3. Jones M. S.,
    4. Jaing C.,
    5. McLoughlin K.,
    6. Gardner S.,
    7. Delwart E. L.

    Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J. Virol. 2010, 84 (12), 6033–6040.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    Code of Federal Regulations, Title 9, Animal and Animal Products (current year): Part 113.53, Requirements for ingredients of animal origin used for production of biologics. Office of the Federal Register, National Archives and Records Administration, U.S. Government Printing Office: Washington DC. January 1, 2010.
17. 17.↵
    1. Chen D.,
    2. Nims R.,
    3. Dusing S.,
    4. Miller P.,
    5. Luo W.,
    6. Quertinmont M.,
    7. Parekh B.,
    8. Poorbaugh J.,
    9. Boose J. A.,
    10. Atkinson E. M.

    Root cause investigation of a viral contamination incident occurred during master cell bank (MCB) testing and characterization—a case study. Biologicals 2008, 36 (6), 393–402.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Brown F.,
    2. Lewis A. M.,
    3. Peden K.,
    4. Krause P.

    1. Hayflick L.

    A Brief History of Cell Substrates Used for the Preparation of Human Biologicals. In Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development; Brown F., Lewis A. M., Peden K., Krause P., Eds.; Karger: Basel, 2001, Vol. 106, pp 5–24.

    OpenUrlPubMed
19. 19.↵
    http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833.htm.
20. 20.↵
    1. Khan A. S.

    Characterization and qualification of cell substrates for manufacturing viral vaccines in the United States. BioProcessing Journal 2009, 8, 8–12.

    OpenUrl
21. 21.↵
    1. Horaud F.,
    2. Brown F.

    1. Erickson G. A.,
    2. Bolin S. R.,
    3. Landgraf J. G.

    Viral Contamination of Fetal Bovine Serum Used for Tissue Culture: Risks and Concerns. In Virological Aspects of the Safety of Biological Products; Horaud F., Brown F., Eds.: Karger: Basel, 1991; Vol. 75, pp 173–175.

    OpenUrl
22. 22.↵
    1. Brown F.,
    2. Lewis A. M.,
    3. Peden K.,
    4. Krause P.

    1. Griffiths E.

    Major Issues Associated with the Use of Cell Substrates for the Production of Vaccines. In Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development; Brown F., Lewis A. M., Peden K., Krause P., Eds.; Karger: Basel, 2001; Vol. 106, pp 25–36.

    OpenUrlPubMed
23. 23.↵
    1. Horaud F.,
    2. Brown F.

    1. Hay R. J.

    Operator-Induced Contamination in Cell Culture Systems. In Virological Aspects of the Safety of Biological Products; Horaud F., Brown F., Eds.; Karger: Basel, 1991; Vol. 75, pp 193–204.

    OpenUrl
24. 24.↵
    1. Merten O. W.

    Virus contaminations of cell cultures—A biotechnological view. Cytotechnology 2002, 39 (2), 91–116.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Petricciani J. C.

    An overview of viral and viral-like agents in cell culture systems. Cytotechnology 1998, 28 (1–3), 49–52.

    OpenUrlPubMed
26. 26.↵
    1. Pastoret P. P.

    Human and animal vaccine contaminations. Biologicals 2010, 38 (3), 332–334.

    OpenUrlPubMed
27. 27.↵
    Center for Biologics Evaluation and Research (CBER). Points to consider in the characterization of cell lines used to produce biologicals. U.S. Food and Drug Administration (FDA): Rockville, MD, July 1993.
28. 28.↵
    CBER. Points to consider in the manufacture and testing of monoclonal antibody products for human use. U.S. FDA: Rockville, MD, February 1997.
29. 29.↵
    CBER. Guidance for industry: Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. U.S. FDA: Rockville, MD, February 2010.
30. 30.↵
    CBER. Guidance for industry: Supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors. U.S. FDA: Rockville, MD, November 2006.
31. 31.↵
    CBER. Guidance for Industry: Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans. April 2003.
32. 32.↵
    Code of Federal Regulations, Title 21, Part 610. Food and Drugs, General Biological Products Standards. Office of the Federal Register, National Archives and Records Administration, U.S. Government Printing Office: Washington, DC. April 1, 2009.
33. 33.↵
    International Conference on Harmonization. ICH Topics Q5D—Guidance on derivation and characterization of cell substrates used for production of biotechnological/biological products. 21 Sept 1998.
34. 34.↵
    International Conference on Harmonisation. ICH Topics Q5A(R1)—Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. 23 Sept 1999.
35. 35.↵
    World Health Organization (WHO). WHO Expert Committee on Biological Standardization, 47^th Report: Requirements for the use of animal cells as in vitro substrates for the production of biologicals. WHO Technical Report Series, No. 878, annex 1., 1998.
36. 36.↵
    1. Ulrey A. K.,
    2. Curren R. D.,
    3. Raabe H. A.

    The importance of supplier qualification for vendors of materials used in in vitro assays. AATEX 14 2008, (Special Issue), 595–600.
37. 37.↵
    1. Wessman S. J.,
    2. Levings R. L.

    Collective experiences of adventitious viruses of animal-derived raw materials and what can be done about them. Cytotechnology 1998, 28 (1–3), 43–48.

    OpenUrlPubMed
38. 38.↵
    1. Harasawa R. M.,
    2. Sasaki T.

    Sequence analysis of the 5′ untranslated region of pestivirus RNA demonstrated in interferons for human use. Biologicals 1995, 23 (4), 263–269.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Harasawa R.,
    2. Tomiyama T.

    Evidence of pestivirus RNA in human virus vaccines. J. Clin. Microbiol. 1994, 32 (6), 1604–1605.

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    1. Nims R. W.

    Detection of adventitious viruses in biologicals—a rare occurrence. Dev. Biol. (Basel) 2006, 123, 153–164.

    OpenUrlPubMed
41. 41.↵
    1. Burstyn D. G.

    Contamination of genetically engineered Chinese hamster ovary cells. Dev. Biol. Stand. 1996, 88, 199–203.

    OpenUrlPubMed
42. 42.↵
    1. Rabenau H.,
    2. Ohlinger V.,
    3. Anderson J.,
    4. Selb B.,
    5. Cinatl J.,
    6. Wolf W.,
    7. Frost J.,
    8. Mellor P.,
    9. Doerr H. W.

    Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV). Biologicals 1993, 21 (3), 207–214.

    OpenUrlCrossRefPubMed
43. 43.↵
    1. Nettleton P. F.,
    2. Rweyemanu M. M.

    The association of calf serum with the contamination of BHK21 clone 13 suspension cells by a parvovirus serologically related to the minute virus of mice (MVM). Arch. Virol. 1980, 64 (4), 359–374.

    OpenUrlPubMed
44. 44.↵
    1. Garnick R. L.

    Experience with viral contamination in cell culture. Dev. Biol. Stand. 1996, 88, 49–56.

    OpenUrlPubMed
45. 45.↵
    1. Fiebig E. W.,
    2. Busch M. P.

    Emerging infections in transfusion medicine. Clin. Lab. Med. 2004, 24 (3), 797–823.

    OpenUrlPubMed